albuterol (Ventolin) vs fluticasone furoate/umeclidinium/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Ventolin)
Marketed by GlaxoSmithKline
NCT00144846 · Phase 3 · completed
Although the registry describes 80 participants as randomized and double-blind, it lists only a single albuterol arm with no placebo or active comparator. The primary endpoint was safety, and no results are posted, so the study cannot provide a controlled comparison of treatment benefit.
Next expected readout: April 2027 · NCT06433921 (registry estimate)
No aligned efficacy figure on record for this race.
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
Reported efficacy
Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)
Result source: NCT02924688
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Ventolin) | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT06657066 | —Trial running · NCT04651777 |
| Trough FEV1, change | 0.1 vs 0.0vs ADVAIR DISKUSNCT0217577114 other results
| 0.1 vs 0.1vs FF/VINCT029246885 other results
|
| ACQ-5, change | —Not posted · NCT06657066 | —Trial running · NCT04651777 |
| OCS dose reduction | —Not posted · NCT06657066 | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- albuterol (Ventolin)
- —Not posted · NCT06657066
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
Trough FEV1, change
- albuterol (Ventolin)
- 0.1 vs 0.0vs ADVAIR DISKUSNCT02175771
14 other results
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.3 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.2 vs 0.1 NCT01479621
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT04937387
- 0.1 vs 0.1 NCT04937387
ACQ-5, change
- albuterol (Ventolin)
- —Not posted · NCT06657066
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
OCS dose reduction
- albuterol (Ventolin)
- —Not posted · NCT06657066
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. albuterol (Ventolin): 4 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | albuterol (Ventolin) | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Dropout rate | 10%100 mg SCa NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results—Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence —Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence 16.7% NCT03924635 · Phase 4 · registry result, not featured evidence · combination 4.8%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence — NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 7.7%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 2.2%100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence — NCT02502734 · Phase 3 · registry result, not featured evidence —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.7% NCT01687296 · Phase 3 · registry result, not featured evidence 12.6%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 16%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 18.5%160 µg NCT00384189 · Phase 3 · registry result, not featured evidence 18.3%80 µg NCT00384189 · Phase 3 · registry result, not featured evidence 16.4%40 µg NCT00384189 · Phase 3 · registry result, not featured evidence —800 μg NCT02479412 · Phase 2 · registry result, not featured evidence —250 μg NCT02479412 · Phase 2 · registry result, not featured evidence —58 μg NCT02479412 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 5.1%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —200 ug NCT06433908 · Phase 1 · registry result, not featured evidence —800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 7.7%100/31.25/25 mcgb NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Discontinued due to AEs | 1%100 mg SCa NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results—Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence —Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence — NCT03924635 · Phase 4 · registry result, not featured evidence · combination —100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence — NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 1.8%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence —100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence — NCT02502734 · Phase 3 · registry result, not featured evidence —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence — NCT01687296 · Phase 3 · registry result, not featured evidence 1.7%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 1.7%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence —160 µg NCT00384189 · Phase 3 · registry result, not featured evidence —80 µg NCT00384189 · Phase 3 · registry result, not featured evidence —40 µg NCT00384189 · Phase 3 · registry result, not featured evidence —800 μg NCT02479412 · Phase 2 · registry result, not featured evidence —250 μg NCT02479412 · Phase 2 · registry result, not featured evidence —58 μg NCT02479412 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —200 ug NCT06433908 · Phase 1 · registry result, not featured evidence —800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 0.7%100/31.25/25 mcgb NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Serious AEs | 3%100 mg SCa NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results0%Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence 0%Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence 4.2% NCT03924635 · Phase 4 · registry result, not featured evidence · combination 11%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 2.3% NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 0.5%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 1.1%100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence 0% NCT02502734 · Phase 3 · registry result, not featured evidence 9.8%200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 6.4%200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5%100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.5%100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 0.8% NCT01687296 · Phase 3 · registry result, not featured evidence 3.4%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 2.5%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 0.6%160 µg NCT00384189 · Phase 3 · registry result, not featured evidence 1.6%80 µg NCT00384189 · Phase 3 · registry result, not featured evidence 1.3%40 µg NCT00384189 · Phase 3 · registry result, not featured evidence 0%800 μg NCT02479412 · Phase 2 · registry result, not featured evidence 0%250 μg NCT02479412 · Phase 2 · registry result, not featured evidence 0%58 μg NCT02479412 · Phase 2 · registry result, not featured evidence 1.9%100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 1%50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0.7%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 3.3%200 ug NCT06433908 · Phase 1 · registry result, not featured evidence 0%800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 4.4%100/31.25/25 mcgb NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Most frequent reported AEs | 100 mg SCa pyrexia 5% headache 3% oropharyngeal pain 3% NCT04276233 · Phase 4 · registry result, not featured evidence show 34 more results100 mg SC headache 28.3% viral upper respiratory tract infection 16.6% bronchitis 13.1% NCT02654145 · Phase 4 · registry result, not featured evidence asthma 0.1% dry mouth 0.1% dysphonia 0.1% NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 50/250 mcg headache 10.4% nasopharyngitis 8.1% bronchitis 5.4% NCT00363480 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · registry result, not featured evidence 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · registry result, not featured evidence 200/62.5/25 mcg nasopharyngitis 32.7% dysgeusia 10.9% eczema 9.1% NCT03184987 · Phase 3 · registry result, not featured evidence 100/10 mcg BID asthma 11% upper respiratory tract infection 9.9% influenza 5.5% NCT02741271 · Phase 3 · registry result, not featured evidence nasopharyngitis 6.9% (placebo 8.3%) headache 5.2% (placebo 13.3%) cough 3.4% (placebo 5%) NCT02502734 · Phase 3 · registry result, not featured evidence 200/12.5 mcg upper respiratory tract infection 18% sinusitis 10.5% nasopharyngitis 9% NCT02175771 · Phase 3 · registry result, not featured evidence 200 mcg upper respiratory tract infection 13.6% cough 10.4% nasopharyngitis 10.4% NCT02175771 · Phase 3 · registry result, not featured evidence 100/12.5 mcg upper respiratory tract infection 17.5% nasopharyngitis 12.5% cough 11.7% NCT02175771 · Phase 3 · registry result, not featured evidence 100 mcg upper respiratory tract infection 18.1% nasopharyngitis 13.4% sinusitis 11.8% NCT02175771 · Phase 3 · registry result, not featured evidence white blood cell count increased 0.8% NCT01687296 · Phase 3 · registry result, not featured evidence 200 µg OD headache 12.6% nasopharyngitis 12.6% bronchitis 6.7% NCT01431950 · Phase 3 · registry result, not featured evidence 100 µg OD bronchitis 11.8% nasopharyngitis 11.8% headache 10.1% NCT01431950 · Phase 3 · registry result, not featured evidence 160 µg pharyngitis 5.2% (placebo 4.8%) upper respiratory tract infection 5.2% (placebo 3.4%) nasopharyngitis 4.2% (placebo 2.1%) NCT00384189 · Phase 3 · registry result, not featured evidence 80 µg upper respiratory tract infection 6.4% (placebo 3.4%) pharyngitis 5.8% (placebo 4.8%) nasopharyngitis 3.2% (placebo 2.1%) NCT00384189 · Phase 3 · registry result, not featured evidence 40 µg nasopharyngitis 6.2% (placebo 2.1%) upper respiratory tract infection 5.9% (placebo 3.4%) pharyngitis 4.6% (placebo 4.8%) NCT00384189 · Phase 3 · registry result, not featured evidence 800 μg nasopharyngitis 11.8% (placebo 15.4%) diarrhoea 8.8% (placebo 0%) headache 5.9% (placebo 0%) NCT02479412 · Phase 2 · registry result, not featured evidence 250 μg headache 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 15.4%) asthma 2.9% (placebo 1.9%) NCT02479412 · Phase 2 · registry result, not featured evidence 58 μg nasopharyngitis 11.8% (placebo 15.4%) gastroenteritis 8.8% (placebo 0%) cough 5.9% (placebo 1.9%) NCT02479412 · Phase 2 · registry result, not featured evidence 100 mcg upper respiratory tract infection 4.9% (placebo 2.9%) nasopharyngitis 2.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 50 mcg nasopharyngitis 6.7% (placebo 4.8%) upper respiratory tract infection 2.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 25 mcg nasopharyngitis 4.8% (placebo 4.8%) upper respiratory tract infection 1.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 12.5 mcg upper respiratory tract infection 6.8% (placebo 2.9%) nasopharyngitis 3.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 200 ug catheter site haematoma 16.7% headache 10% abdominal pain 6.7% NCT06433908 · Phase 1 · registry result, not featured evidence 800 ug catheter site related reaction 30% headache 16.7% cough 10% NCT06433908 · Phase 1 · registry result, not featured evidence | 100/31.25/25 mcgb nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · combination · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 FF 200 ug, UMEC 62.5 ug, VI 25 ug covid-19 5.7% nasopharyngitis 4.5% upper respiratory tract infection 4.5% NCT04937387 · Phase 3 · Asthma · phase 3 FF 100 ug, UMEC 62.5 ug, VI 25 ug upper respiratory tract infection 7.8% covid-19 3.3% nasopharyngitis 3.3% NCT04937387 · Phase 3 · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · combination 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · combination |
Notes
- aPopulation comparability has not been reviewed for 31 of these studies.
- bPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
albuterol (Ventolin)
show 1 more result
show 6 more results
show 1 more result
show 4 more results
show 1 more result
show 1 more result
show 1 more result
+ 40 further endpoints in the CSV export.
fluticasone furoate/umeclidinium/vilanterol
show 3 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Ventolin)'s landscape · fluticasone furoate/umeclidinium/vilanterol's landscape